TCBP | TC Biopharm (Holdings) Plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.4600 - 2.6000
52 Week Range	2.0300 - 523.20
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	164,134
Average Volume	217,590
Shares Outstanding	30,907
Market Cap	385
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-02-11

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-4,684.40
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	41
Country	UK
Website	TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBP's peers: APCX, ZVSA, PALI, UNCY, APGN, IMMX, REVB, ZURA, PHIO, RNAZ, ICU, VIRI, SONN, QNRX, ALLR, KRBP, VRAX, BDRX, BWV, PXMD, HILS, GGROW

*Chart delayed

Analyzing fundamentals for TCBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TCBP Fundamentals page.

Watching at TCBP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on TCBP Technicals page.